iFIT Cluster of Excellence Newsletter Vol. III |
|
|
Dear members,
With our Email Newsletter, we keep you up to date with all new information surrounding our “Image-Guided and Functionally Instructed Tumor Therapies” Cluster of Excellence. The newsletter appears periodically.
If you have any comments or feedback feel free to get in touch with us: ifitoffice@med.uni-tuebingen.de With best regards,
iFIT Office Team |
|
|
| Protection for Cancer Patients
|
|
|
| The Chameleon among Tumors - Neuroendocrine Tumors
|
|
|
| Prof. Nikolaou elected as new President of the German Radiological Society
|
|
|
| Workshop in International STEM Communication
|
|
|
| Children's University Researcher Day 2023 |
|
|
| A Visit from the Far East |
|
|
| 1st International iFIT Conference - Aftermovie
|
|
|
| Nature Biomedical Engineering Publication
|
|
|
| Nature Reviews Cancer Publication |
|
|
| iFIT Seminar Series with Dr. Erik Aarntzen
11th of September 2023 from 12:00pm - 1:00pm
Medical Clinic, Big Lecture Hall, Otfried-Müller-Str. 10 |
|
|
| iFIT Workshop "Präsentationsrhetorik"
14th - 15th of September 2023 from 9:00am - 4:30pm
iFIT Building, Conference Room, Röntgenweg 11 |
|
|
| Farewell Symposium for Prof. Hans-Georg Rammensee
29th of September 2023 from 1:00pm - 5:00pm
"Botanik" Building, Hörsaal N10, Auf der Morgenstelle 3
|
|
|
| iFIT Women in Science Symposium
6th of October 2023 from 1:00pm - 4:45pm
Gesundheitszentrum, Tagungsraum 1 und 2
Hoppe-Seyler-Str. 6 |
|
|
| iFIT Seminar Series with Prof. David Heppner 9th of October 2023 from 3:00pm - 4:00pm
Medical Clinic, Big Lecture Hall, Otfried-Müller-Str. 10
|
|
|
| iFIT Scientific Symposium & General Assembly
23rd of October 2023 from 8:45am - 06:30pm
Westspitze, Eisenbahnstraße 1
|
|
|
| iFIT Lunch & Learn Session with Prof. Matthias Gehringer
15th of November 2023 from 12:30pm - 1:30pm
Medical Clinic, Big Lecture Hall, Otfried-Müller-Str. 10
|
|
|
Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants |
Junker D., […], Nelde, A. et al. "Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants" Clin Infect Dis. 2023 Feb 8;76(3):e240-e249. 10.1093/cid/ciac498 IF: 20.9 |
Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system |
Renovanz, M., […], Biskup, S., […] Zender, L. et al. “Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system.” Neurooncol Adv. 2023 Feb 14;5(1):vdad012.
10.1093/noajnl/vdad012 IF: 9.3 |
Noninvasive Detection of Smooth Muscle Cell-Derived Hot Spots to Study Atherosclerosis by PET/MRI in Mice |
Feil, S., Stowbur, D., Schörg B. et al. Noninvasive Detection of Smooth Muscle Cell-Derived Hot Spots to Study Atherosclerosis by PET/MRI in Mice. Circ Res. (2023). https://pubmed.ncbi.nlm.nih.gov/36794593/ IF: 23.2 |
Significant impact of time-of-day variation on metformin pharmacokinetics |
Türk, D.,[…], Schwab, M. et al. “Significant impact of time-of-day variation on metformin pharmacokinetics." Diabetologia 2023 Jun;66(6):1024-1034. 10.1007/s00125-023-05898-4 IF: 10.4 |
Decorin improves human pancreatic β-cell function and regulates ECM expression in vitro |
Urbanczyk, M., [...], Marzi, J. et al. “Decorin improves human pancreatic β-cell function and regulates ECM expression in vitro." Matrix Biol. 2023 Jan;115:160-183. 10.1016/j.matbio.2022.12.005 IF: 10.4 |
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency |
Heitmann, J.S., Tandler, C., Marconato, M. et al. Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency. Nat Commun 14, 5032 (2023). https://doi.org/10.1038/s41467-023-40758-0 IF: 16.6
|
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease |
Heitmann, J.S., [...] Walz, J., [...] Salih, H. et al. Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease. J Hematol Oncol. 2023 Aug 17;16(1):96. 10.1186/s13045-023-01490-w.
IF: 28.5
|
|
|
Postdoc (m/f/d) with focus on T-cell immunology
Department of Peptide-based Immunotherapy |
Postdoc (m/f/d)
Department of Peptide-based Immunotherapy
|
|
|
Follow us on social media
|
Legal Notice
Cluster of Excellence “Image-Guided and Functionally Instructed Tumor Therapies” (iFIT)
Röntgenweg 11
72076 Tübingen, Germany Contact:
Public Relations
Steven Pohl Mail: steven.patrick.pohl@med.uni-tuebingen.de Click here to unsubscribe
|
|
|
|
